Qing Hai Zhao
Corporate Officer/Principal bei ADAGENE INC.
Aktive Positionen von Qing Hai Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ADAGENE INC. | Corporate Officer/Principal | 01.10.2020 | - |
Karriereverlauf von Qing Hai Zhao
Ehemalige bekannte Positionen von Qing Hai Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FORTY SEVEN, INC. | Corporate Officer/Principal | 01.01.2017 | 01.10.2020 |
| ANAPTYSBIO, INC. | Corporate Officer/Principal | 01.01.2016 | 01.01.2017 |
| NGM BIOPHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.01.2014 | 01.01.2016 |
| Corporate Officer/Principal | 01.01.2014 | 01.01.2016 |
Ausbildung von Qing Hai Zhao
| East China University of Science & Technology | Undergraduate Degree |
| University of Uppsala | Doctorate Degree |
| Zhongshan Hospital Fudan University | Graduate Degree |
Statistik
International
| China | 4 |
| Vereinigte Staaten | 4 |
| Schweden | 2 |
Operativ
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ADAGENE INC. | Health Technology |
| ANAPTYSBIO, INC. | Health Technology |
| NGM BIOPHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
- Börse
- Insiders
- Qing Hai Zhao
- Erfahrung